Literature DB >> 15528136

Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment.

Magda De Smedt1, Inge Hoebeke, Jean Plum.   

Abstract

In this paper, we confirm data reported by the group of Zúñiga-Pflücker that human cord blood CD34(+)38(-)Lin- progenitor cells when co-cultured with the murine stromal cell line OP9-DL engineered to express the Notch ligand delta-like-1 mature into T lymphocytes with a phenotypic progression as the one seen in thymus. We show that this is also the case for human T cells starting from CD34(+) adolescent bone marrow cells. These findings offer the theoretical possibility to generate ex vivo human T cells and administer them in vivo in patients to overcome their immune deficient window period after transplantation. However, the practical and theoretical problems that this new technology has to overcome before this technique can be applied in clinic are still enormous and discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528136     DOI: 10.1016/j.bcmd.2004.08.007

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  43 in total

1.  Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1.

Authors:  Mari H Dallas; Barbara Varnum-Finney; Paul J Martin; Irwin D Bernstein
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 2.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

Review 3.  Clinical strategies to enhance T cell reconstitution.

Authors:  Gabrielle L Goldberg; Johannes L Zakrzewski; Miguel A Perales; Marcel R M van den Brink
Journal:  Semin Immunol       Date:  2007-10-26       Impact factor: 11.130

4.  Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.

Authors:  Colin H Martin; Petter S Woll; Zhenya Ni; Juan Carlos Zúñiga-Pflücker; Dan S Kaufman
Journal:  Blood       Date:  2008-07-11       Impact factor: 22.113

Review 5.  Molecular mechanisms that control mouse and human TCR-alphabeta and TCR-gammadelta T cell development.

Authors:  Tom Taghon; Ellen V Rothenberg
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

6.  Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

Authors:  Johannes L Zakrzewski; David Suh; John C Markley; Odette M Smith; Christopher King; Gabrielle L Goldberg; Robert Jenq; Amanda M Holland; Jeremy Grubin; Javier Cabrera-Perez; Renier J Brentjens; Sydney X Lu; Gabrielle Rizzuto; Derek B Sant'Angelo; Isabelle Riviere; Michel Sadelain; Glenn Heller; Juan Carlos Zúñiga-Pflücker; Chen Lu; Marcel R M van den Brink
Journal:  Nat Biotechnol       Date:  2008-03-30       Impact factor: 54.908

Review 7.  Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation.

Authors:  Enrico Velardi; Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Immunol Lett       Date:  2013-10-08       Impact factor: 3.685

8.  T-lymphoid differentiation potential measured in vitro is higher in CD34+CD38-/lo hematopoietic stem cells from umbilical cord blood than from bone marrow and is an intrinsic property of the cells.

Authors:  Magda De Smedt; Georges Leclercq; Bart Vandekerckhove; Tessa Kerre; Tom Taghon; Jean Plum
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

Review 9.  Emerging strategies to boost thymic function.

Authors:  Georg A Holländer; Werner Krenger; Bruce R Blazar
Journal:  Curr Opin Pharmacol       Date:  2010-05-04       Impact factor: 5.547

Review 10.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.